Objective:To analyze the effect of combination of bevacizumab and immunotherapy in the clinical treatment of patients with non-squamous non-small cell lung cancer.How:A total of 60 patients with non-squamous non-small cell lung cancer admitted to hospital were selected and divided into 2 groups with 30 patients in each group by random number table method.Immunotherapy(tirellizumab,carrilizumab or sindillizumab)and anti-angiogenic therapy(bevacizumab)were given,respectively.Clinical effects,tumor marker levels and adverse reactions were analyzed.Results:The total effective rate of observation group was significantly higher than that of control group(P＜0.05).After treatment,the tumor marker content in observation group was better than that in control group(P＜0.05),and there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:The combination of bevacizumab and immunotherapy has a good effect on the improvement of non-squamous non-small cell lung cancer and the side effects can be tolerated,which is worthy of widespread clinical promotion and application.
bevacizumabimmunotherapyantiangiogenic therapynon-squamous non-small cell lung cancer
NETL
NSTL
万方数据
